No insider purchase over the last 90 days. The latest, by 정병석, was filed 07 Aug 2026.
AbClon Inc.: what insiders have been doing
Headquartered in South Korea, AbClon Inc. belongs to the Health Care sector and traces its origins to 2010. Filings by its managers are published through DART (FSS). From 2 November 2025 to 2 November 2026, the disclosure feed for AbClon Inc. logged 13 filings by 10 insiders.
Both sides are active: 11 purchases worth €616k and 1 sale, from 8 insiders and 1 insider respectively. The amount is not disclosed for 6 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 이종서 filed the largest purchase, €506k, on 23 March 2026, which represents 0.14% of the company's market value. The buyers include 5 board members and 2 senior executives.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 13 filings, this issuer sits above that mark. Since 2021, the database holds 16 purchases and 12 sales by insiders of the company.
Within a 30-day window, 4 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase dates back some time: it was published 95 days ago, on 7 August 2026. Filings reach the DART (FSS) feed a median of 7 days after the trade. That lag is the time during which only the insider knows about the trade.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Key facts
Headquarters: South Korea · Founded: 2010
Source: Wikidata (CC0).
Who traded when
BuySale+2 other insiders
Since the insiders bought
- -58.7%Entry ₩44,700 · Close 30 Oct 2026 ₩18,470
- -58.7%Entry ₩44,700 · Close 30 Oct 2026 ₩18,470
- -58.7%Entry ₩44,700 · Close 30 Oct 2026 ₩18,470
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 40 sharesShareKRXDART:20260807000560Canonical exit: 5 Nov 2026 (T+90)
- 264 shares0.0019% mcap1.3% of flowKRXDART:20260507000630Canonical exit: 26 Jul 2026 (T+90)
- 3,231 shares@ ₩14,678.03560.0075% mcap100.0% of flowShareKRXDART:20260507000626Canonical exit: 21 Apr 2026 (T+90)
- 1,033 shares@ ₩16,791.000.0027% mcap100.0% of flowShareKRXDART:20260507000622Canonical exit: 26 Jul 2026 (T+90)
- 1,000 shares0.0088% mcap5.9% of flowKRXDART:20260403001054Canonical exit: 2 Jul 2026 (T+90)
- 1,000 shares@ ₩60,000.000.0094% mcap100.0% of flowShareKRXDART:20260403000940Canonical exit: 2 Jul 2026 (T+90)
- 12,500 shares0.14% mcap92.8% of flowKRXDART:20260323001107Canonical exit: 21 Jun 2026 (T+90)
- ●Executives0DART
- 127,325 sharesKRXDART:20260108000506Canonical exit: 1 Apr 2026 (T+90)
- 5,000 sharesShareKRXDART:20260108000461Canonical exit: 8 Apr 2026 (T+90)
- 39,925 sharesShareKRXDART:20260108000482Canonical exit: 8 Apr 2026 (T+90)
- 50,000 sharesShareKRXDART:20260108000471Canonical exit: 8 Apr 2026 (T+90)
- 48,905 sharesKRXDART:20251209000014
- 498,612 sharesKRXDART:20240610000272
- 498,612 sharesKRXDART:20230811001085
- ShareKRXDART:20230811001122Canonical exit: 6 Nov 2023 (T+90)
- 498,612 sharesKRXDART:20230706000308
- ShareKRXDART:20230706000318Canonical exit: 1 Oct 2023 (T+90)
- 498,612 sharesKRXDART:20230615000350
- ShareKRXDART:20230615000357Canonical exit: 7 Sept 2023 (T+90)
- 498,612 sharesKRXDART:20230331003195
- ●Executives0DART
- ●Executives0DART
- 498,612 sharesKRXDART:20221226000407
- ShareKRXDART:20221226000409Canonical exit: 26 Mar 2023 (T+90)
25 of 32 declarations
About AbClon Inc.
AppClone is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for disease treatment.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
